Management Approach for Elevated Liver Enzymes

Initial Diagnostic Evaluation

The American College of Gastroenterology recommends determining the pattern of liver enzyme elevation to guide further workup, with hepatocellular pattern suggesting evaluation for viral hepatitis, drug-induced liver injury, alcohol-related liver disease, and non-alcoholic fatty liver disease, and cholestatic pattern suggesting evaluation for biliary obstruction, primary biliary cholangitis, primary sclerosing cholangitis, and drug-induced cholestasis 1

The American Association for the Study of Liver Diseases recommends obtaining a complete liver panel, including ALT, AST, ALP, GGT, total and direct bilirubin, albumin, and prothrombin time, to assess liver function 1
Checking GGT when ALP is elevated can help confirm hepatobiliary origin, as GGT tends to be proportionately more elevated in cholestatic rather than hepatocellular liver injury, according to the European Association for the Study of the Liver 2

The American College of Radiology recommends performing abdominal ultrasound to assess liver structure, rule out biliary obstruction, and detect fatty infiltration 1
The European Association for the Study of the Liver suggests considering liver and splenic stiffness measurement by ultrasound-based or MR-based elastography to help identify portal hypertension in patients with suspected cirrhosis 2

For mild elevations, the American College of Gastroenterology recommends identifying and removing potential causative agents, including hepatotoxic medications, and implementing lifestyle modifications for non-alcoholic fatty liver disease 1
For moderate to severe elevations, the American Association for the Study of Liver Diseases recommends immediately discontinuing all potentially hepatotoxic medications and performing an expeditious and complete diagnostic evaluation 1

The European Association for the Study of the Liver recommends discontinuing the suspected causative agent for drug-induced liver injury and monitoring liver tests following treatment cessation for at least five half-lives of the drug and major metabolites 2
The National Comprehensive Cancer Network suggests that for immune checkpoint inhibitor-induced liver injury, treatment should be continued with close monitoring for Grade 1 elevations, held temporarily for Grade 2 elevations, and permanently discontinued for Grade 3-4 elevations 4

The American Association for the Study of Liver Diseases notes that serum ALP is commonly elevated in patients with malignancy and should not be used alone to determine eligibility for clinical trials 2
The European Association for the Study of the Liver recommends obtaining two pre-treatment ALT values when possible to exclude rapidly rising ALT from alternative causes in patients with elevated baseline ALT 2

The American College of Gastroenterology recommends monitoring liver enzymes routinely before administration of each cycle of treatment or at least monthly for patients on hepatotoxic medications 2
The American Association for the Study of Liver Diseases suggests continuing monitoring until normalization or stabilization of liver enzymes 1

The American College of Gastroenterology warns against ignoring mild, persistent elevations, as even mild elevations persisting beyond 6 months warrant thorough evaluation 1
The American Association for the Study of Liver Diseases cautions against attributing all elevations to fatty liver without excluding other causes 1